Herpes zoster: The associated burden and its prevention;Le zona : Son fardeau et sa prévention

Geriatrie et Psychologie Neuropsychiatrie du Vieillissement

Volumn 9, Issue 4, 2011, Pages 391-397

  Lang, Pierre Olivier ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Antiviral therapy; Herpes zoster; Post herpetic neuralgia; Prevention; Vaccination

Indexed keywords

ANTIVIRUS AGENT; VARICELLA ZOSTER VACCINE;

AGED; COST OF ILLNESS; CROSS-SECTIONAL STUDY; FEMALE; FRAIL ELDERLY; HEALTH SURVEY; HERPES ZOSTER; HUMAN; MALE; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PREVENTIVE HEALTH SERVICE; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SWITZERLAND; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; FEMALE; FRAIL ELDERLY; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; IMMUNIZATION PROGRAMS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; RISK FACTORS; SWITZERLAND;

EID: 79960912836     PISSN: 21158789     EISSN: 21157863     Source Type: Journal    
DOI: 10.1684/pnv.2011.0273     Document Type: Article

References (51)

1. Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. Cell 2010 ; 138: 30-50.
2. Gilden DH, Kleinschmidt-De Masters BK, La Guardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicellazoster virus. N Eng J Med 2000 ; 342: 635-45. (Pubitemid 30118417)
3. Kilgore PE, Kruzon-Moran D, Seward JF. Varicella in Americans from NHANES III: implication or control through routine immunization. J Med Virol 2003 ; 70: S111-S8.
4. Gnann JW, Whitley RJ. Herpes zoster. N Eng J Med 2002 ; 347: 340-6. (Pubitemid 34815357)
5. Gershon AA, Perkin RT. Herpes zoster. N Eng J Med 2000 ; 343: 222.
6. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster ?. Lancet Infect Dis 2004 ; 4: 26-33. (Pubitemid 38057055)
7. Hope-Simpson RE. Epidemiology of shingles. J Roy Med Soc Med 1991 ; 84: 184.
8. Lang PO, Belmin J, Michel JP. Herpes zoster in old adults. Press Med 2009 ; 38: 571-83.
9. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Eng J Med 2005 ; 352: 2271-84.
10. Oxman MN, Levin MJ. Shingles Prevention Study Group. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis 2008 ; 197(Suppl. 2): S228-36. (Pubitemid 351590176)
11. Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010 ; 48(Suppl 1): S2-S7.
12. Lang PO, Mitchell WA, Lapenna A, Pitts D, Aspinall R. Immunological pathogenesis of main age-related diseases and frailty: role of immunosenescence. European Geriatric Medicine 2010 ; 1: 112-21.
13. Lang PO, Hasso Y, Michel JP. Stop shingles in its tracks. J Fam Pract 2009 ; 58: 531-4.
14. Schmader K. Herpes zoster and postherpetic neuralgia in older adults. Clin Geriatr Med 2007 ; 23: 615-32, vii-viii. (Pubitemid 47042344)
15. Wareham DW, Breuer J. Herpes zoster. BMJ 2007 ; 334: 1211-5. (Pubitemid 46954586)
16. Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J. The burden of herpes zoster: a prospective population based study. Vaccine 2006 ; 24: 1308-14. (Pubitemid 43222038)
17. Lang PO, Herrmann F, Michel JP. Varicella-zoster vaccine. N Engl J Med 2007 ; 357: 89.
18. Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007 ; 44: S1-S26. (Pubitemid 44956795)
19. Johnson RW. Herpes zoster in the immunocompetent patient: management of post-herpetic neuralgia. Herpes 2003 ; 10: 38-45. (Pubitemid 37486590)
20. Chidiac C, Buxelles J, Daures JP, Hoang-Xuan T, Morel P, Leplege A, et al. Characteristics of patients with herpes zoster on presentation to practioners in France. Clin Infect Dis 2001 ; 33: 62-9. (Pubitemid 32554504)
21. Stein AN, Britt H, Harrison C, Conway EL, Cunningham A, MacIntyre CR. Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine 2009 ; 27: 520-9.
22. McGuire T,Wells KB, Bruce ML, Miranda J, Scheffer R, Durham M, et al. Burden of illness. Ment Health Serv Res 2002 ; 4: 179-85. (Pubitemid 36032780)
23. Lang PO, Pautex S, Belmin J, Michel JP. Herpes zoster-related pain in aged individuals: how to manage it safely. European Geriatric Medicine 2010 ; 1: 273-8.
24. Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ 2010 ; 182: 1731-6.
25. Granger CV. Mesure de l'indépendance fonctionnelle (MIF). L'évaluation en rééducation. In: Actes des 6es entretiens de l'Institut de Garches. Paris: Arnette, 1987: 13-20.
26. Granger CV, Hamilton BB, Linacre JM, Heinemann AW,Wright BD. Performance profiles of the functional independence measure. Am J Phys Med Rehabil 1993 ; 72: 84-9. (Pubitemid 23144146)
27. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectivness of vaccination in England andWales. Vaccine 2001 ; 19: 3076-90. (Pubitemid 32324035)
28. Jung BF, Johnson RW, Griffin DR, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004 ; 62: 1545-51. (Pubitemid 38608193)
29. Weinberg A, Levin MJ. VZV T cell-mediated immunity. Curr Top Microbiol Immunol 2010 ; 342: 341-57.
30. Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caulfield MJ, et al. US Department of Veterans Affairs (VA) Cooperative Studies Program Shingles Prevention Study Investigators. Varicellazoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009 ; 200: 1068-77.
31. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007 ; 132: 237-51. (Pubitemid 350051570)
32. Kost RG, Strauss SE. Postherpeticneuralgia: pathogenesis, treatment, and prevention. N Eng J Med 1996 ; 335: 32-42.
33. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Eng J Med 2007 ; 356: 1338-43. (Pubitemid 46513299)
34. Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med 2005 ; 352: 2266-7. (Pubitemid 40740549)
35. Levin MJ, Murray M, Zerbe GO, White CJ, Hayward AR. Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine. J Infect Dis 1994 ; 170: 522-6. (Pubitemid 24262250)
36. Levin MJ, Hayward AR. The varicella vaccine. Prevention of herpes zoster. Infect Dis Clin North Am 1996 ; 10: 657-75. (Pubitemid 26285293)
37. Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebocontrolled trial. J Pain Symptom Manage 1997 ; 13: 327-31. (Pubitemid 27280025)
38. Kuraishi Y, Takasaki I, Nojima H, Shiraki K, Takahata H. Effects of the suppression of acute herpetic pain by gabapentin and amitriptyline on the incidence of delayed postherpetic pain in mice. Life Sci 2004 ; 74: 2619-26. (Pubitemid 38369359)
39. van Wijck AJ, Opstelten W, Moons KG, van Essen GA, Stolker RJ, Kalkman CJ, et al. The PINE study of epidural steroids and local anaesthetics to prevent postherpeticneuralgia: a randomised controlled trial. Lancet 2006 ; 367: 219-24. (Pubitemid 43107666)
40. Johnson RW, Dworkin RH. Treatment of herpes zoster and postherpetic neuralgia. BMJ 2003 ; 326: 748-50. (Pubitemid 36408042)
41. Jackson JL, Gibbons R, Meyer G, Inouye L. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A meta-analysis. Arch Intern Med 1997 ; 157: 909-12. (Pubitemid 28337042)
42. Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996 ; 22: 341-7. (Pubitemid 26056166)
43. Whitley RJ,Weiss H, Gnann Jr. JW, Tyring S, Mertz GJ, Pappas PG, et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med 1996 ; 125: 376-83.
44. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995 ; 39: 1546-53.
45. Tyring S, Barbarash RA, Nahlik JE, Cunningham A, Marley J, Heng M, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med 1995 ; 123: 89-96.
46. Tyring S, Engst R, Corriveau C, Robillard N, Trottier S, Van Slycken S, et al. Famciclovir for ophthalmic zoster: a randomized aciclovir controlled study. Br J Ophthalmol 2001 ; 85: 576-81. (Pubitemid 32397834)
47. Schmader KE, Johnson GR, Saddier P, Ciarleglio M, Wang WW, Zhang JH, et al. ; Shingles Prevention Study Group. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc 2010 ; 58: 1634-41.
48. Weinberg A, Lazar AA, Zerbe GO, Hayward AR, Chan IS, Vessey R, et al. Influence of age and nature of primary infection on varicellazoster virus-specific cell-mediated immune responses. J Infect Dis 2010 ; 201: 1024-30.
49. Centers for Disease Control and Prevention (CDC). Prevention of Herpes zoster recommendations of the advisory committee on immunization practices (ACIP). MMWR 2008 ; 57: 1-30.
50. Lu P, Euler GL, Jumaan AO, Harpaz R. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: Uptake of the first new vaccine to target seniors. Vaccine 2009 ; 27: 882-7.
51. Centers for Disease Control and Prevention (CDC). Adult immunization programs in nontraditional settings: quality standards and guidance for program evaluation - a report of the National Vaccine Advisory Committee. MMWR 2000 ; 49: RR-1.